CD4 and meningoencephalitis: Almost a decade ago, the first trial of anti-Aβ42 immune treatment in AD patient showed promising efficacy, with a slower rate of cognitive decline, [21,55] however 6% of treated patients developed meningoencephalitis due to Aβ42 specific CD4+ T-cell infiltration in brain [56,57].